• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Management of Chronic Coronary Disease: A Guideline Topline in 10 Take-Home Messages

Commentary
Slideshow

The 10 take-home points from the ACC/AHA cover diet, exercise, cardiac rehab, use of new treatments, reliance on statins, guidance on beta-blockers, plus more.

The 2023 clinical practice guideline on management of patients with chronic coronary disease issued by a joint committee of the American Heart Association and American College of Cardiology is the first update on the topic since 2012, reflecting published studies, reviews and meta-analyses identified in a comprehensive review conducted from September 2021 to May 2022.

Updates to the 2023 recommendations incorporate evidence for including new therapies in treatment plans, for discontinuing use of older therapies, for extending or truncating duration of therapies, and for increasing focus on the role of social determinants of health in the etiology of disease and the barriers they may pose to reducing morbidity and mortality.

The joint committee identified "Top 10 Take-Home Messages" from the guideline, and these are described in this Topline, along with their application for patients who have, or at risk of developing cardiovascular disease.


Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2025 MJH Life Sciences

All rights reserved.